DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”)
(NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the
life sciences industry, today announced the appointment of Ron Bruehlman as Executive Vice President and interim
Chief Financial Officer, succeeding Mike McDonnell who is leaving the company to become Chief Financial Officer
of Biogen Inc.
Ron was previously the Chief Financial Officer of IMS Health from 2011 until the merger of IMS Health and
Quintiles in 2016. Since the merger, Ron has continued to play an active role on the executive leadership team
at IQVIA, serving as a senior advisor to Ari Bousbib, Chairman and CEO of IQVIA. During this time, Ron regularly
participated in key management meetings, operational reviews, preparation of quarterly earnings reports, and
board meetings, providing on-going guidance and support to Mike and the senior finance team. In addition, Ron
currently serves as Chairman of the Board of Directors at Q2 Solutions, an IQVIA and Quest
Diagnostics joint venture and a leading clinical trial laboratory services organization. He has an excellent
understanding of IQVIA’s strategy, operations, customers and the healthcare industry.
Prior to joining IMS Health, Ron had a 23-year career at United Technologies Corporation (UTC), where he held
multiple senior finance leadership roles of increasing responsibility. These included leading the finance
function at UTC Commercial, Chief Financial Officer of Carrier Corporation, heading the corporate financial
planning and analysis function for UTC and leading UTC’s investor relations function. Ron earned a B.S. in
economics from the University of Delaware, as well as an MBA in finance from the University of Chicago, Booth
School of Business.
“I am thrilled Ron has agreed to serve as our interim CFO. I have known and worked continuously with Ron for
nearly 25 years. Ron is a world class CFO with outstanding strategic and operational skills, a deep knowledge of
our company and industry, as well as extensive experience in leading large global finance organizations,” said
Ari Bousbib, Chairman and CEO of IQVIA. Bousbib added, “Ron is widely respected and admired across IQVIA and
will assume this role seamlessly. I want to thank Mike for his contributions to IQVIA and wish him well in his
new role.”
“I am excited to continue serving the company as we navigate through the COVID-19 situation, execute the
strategy that we first envisioned at the time of the merger, and drive towards achievement of our Vision 22
goals,” said Mr. Bruehlman.
“I am extremely grateful for the opportunity Ari gave me to be a part of this great company and proud of what
the team has accomplished. IQVIA is on a uniquely attractive strategic path and as a shareholder, I look forward
to IQVIA’s continued success. Ron and I have worked hand-in-hand over the past four years and this will be an
easy and immediate transition,” said Mr. McDonnell.
IQVIA will engage in a methodical process to consider a long-term successor. The company will evaluate several
highly qualified internal candidates as well as external candidates. Mr. Bruehlman’s appointment is effective
from August 1, 2020.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research
services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies
human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of
human science — to enable companies to reimagine and develop new approaches to clinical development and
commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA
CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics,
transformative technology and extensive domain expertise, as well as execution capabilities. With approximately
67,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of
privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing
information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the
precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help
biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other
healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in
an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
IQVIAFIN
View source version on businesswire.com:
https://www.businesswire.com/news/home/20200708005815/en/
Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com)
+1.973.257.7144
Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com)
+1.484.567.6732
Source: IQVIA Holdings Inc.